The aim of this presentation is to highlight the clinicalinteractions between herbal product and prescribeddrugs.

Slides:



Advertisements
Similar presentations
The management of adverse drug reactions I Ralph Edwards
Advertisements

Pharmacology for Anesthesia I Introduction. What is a Drug?
Improving Candidate Quality Through the Prediction of Clinical Outcome.
FDA Pharmacogenetic Labels A Clinical Perspective David A Flockhart MD, PhD Indiana University School of Medicine Clinical Pharmacology Subcommittee of.
PHT 415 BASIC PHARMACOKINETICS Course Instructor:Prf. Dr. Hnaa elsaghir Assistant lecturers, Doaa elshora and eman elfakih Text: Hand book of basic pharmacokinetics,
Pharmacotherapy in the Elderly Paola S. Timiras May, 2007.
Pharmacotherapy in the Elderly Judy Wong
What Do Toxicologists Do?
New Zealand College of Pharmacists
Chapter 6 Drug Interactions 1.
Guidelines to Lower Risk of Drug-Nutrient Interactions
Prepared By Dr Shaheen Delivered By Dr Naser
Yasar Kucukardali Professor, Internal Medicine Yeditepe University.
Background: Focus on P-gp Questions:
Pharmacologic Principles Chapter 1, 2, 3. Understanding Nurses must understand both + and – effects of drugs Pharmacotherapeutics –u–use of drugs and.
How and Why Drugs Work Chapter 5
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Mark Bleackley MEDG 505 March.
Copyright © 2006 Pearson Education, Inc., publishing as Benjamin Cummings PowerPoint® Lecture Slide Presentation prepared by Michael Hall 23 Complementary.
Pharmacokinetics: Bioavailability Asmah Nasser, M.D.
Introduction to Pharmacotherapy Ghada A Bawazeer. MSc, PharmD. BCPS King Saud University-College of Pharmacy Sept
Biomedical Research Objective 2 Biomedical Research Methods.
Biomedical Research.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Introduction to Pharmacology PHARM TECH. Pharmacology  Pharmacology is the science that deals with the study of therapeutic (beneficial) agents.  Knowledge.
Problems of Polypharmacy
Lecture 6 II. Non-receptor Mechanisms. Direct Physical blocking of channel local anesthetic & amiloride Modulator Bind to the channel protein itself Ca.
Chapter 4 Pharmacokinetics Copyright © 2011 Delmar, Cengage Learning.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
BASIC PHARMACOLOGY 2 SAMUEL AGUAZIM(MD).
Bioequivalence Dr Mohammad Issa Saleh.
May 19, 2005FDA Antiviral Drugs Advisory Committee Meeting 1 Tipranavir NDA Drug Interactions Yuanchao (Derek) Zhang, Ph.D. Clinical Pharmacology.
1 Pharmacokinetics: Introduction Dr Mohammad Issa.
Introduction What is a Biowaiver?
Shirley M. Tsunoda Liver Transplant, Drug Metabolism/PK Research Interests Investigating the genetic and environmental factors that influence variability.
Signal identification and development I.Ralph Edwards.
© Paradigm Publishing, Inc.1 Chapter 2 Basic Concepts of Pharmacology.
Challenges to drug design Did you know? Over 2 million people are hospitalized each year for adverse reactions to prescription drugs. Over 2 million.
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
1 Transporters and Their Role in Drug Interactions.
PHT 415 BASIC PHARMACOKINETICS
Foundation Knowledge and Skills
Complementary and Alternative Medicine 1. Complementary and Alternative therapies tend to focus on the whole person, taking into consideration an individual’s.
Basic Concepts of Pharmacology © Paradigm Publishing, Inc.
Drug efficacy is questioned.. Variation in drug responses.
Copyright © 2016 by Elsevier, Inc. All rights reserved. Geropharmacology.
Meet & Greet. Welcome Objectives: 1. Review the core terminology used in pharmacology. 2. Discuss the features of the “perfect” drug. 3. Examine the.
Tanzania, August 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Bioequivalence dossier requirements for the prequalification project WHO Training Workshop.
Focus On Nonvitamin/ Nonmineral Supplements. Copyright 2010, John Wiley & Sons, Inc. Types of Dietary Supplements.
Pharmacology Science that studies interactions of drugs with organism on different levels (subcellular, cellular, organ, systemic) Studies: - relationship.
Introduction to general pharmacology.
The Stages of a Clinical Trial
Public health education
5 Pharmacodynamics.
Drug Discovery &Development
Pharmacology Tutoring – Factors Affecting Drug Action
Introduction What is a Biowaiver?
Toxicology Drug Poisioning.
By: Dr. Roshini Murugupillai
Drug Elimination Drug elimination consists of 2 processes
APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY
An Introduction to Medicinal Chemistry 3/e
Toxicology Drug Poisioning.
Biopharmaceutics Dr Mohammad Issa Saleh.
5 Pharmacodynamics.
Introduction; Scope of Pharmacology Routes of Drug Administration
Clinical Pharmacokinetics
Pharmacologic Principles – Chapter 2
Clinical Pharmacokinetics
By Amany Helmy Hasanin Assistant Professor of Clinical Pharmacology
Objective 2 Biomedical Research Methods
Presentation transcript:

The aim of this presentation is to highlight the clinicalinteractions between herbal product and prescribeddrugs.

► Mechanism of Drug- Herb interactions ► Literature review ► Systematic review ► Strategies to minimize Drug-Herb interaction

Introduction Surveys show that two-thirds of womenuse herbs for perimenopausal symptoms, 45% of parentsgive their children herbal treatments and 45% ofpregnant women try herbal remedies. 16% of prescription drug users consume herbal sup-plements

The altered drug response of herb-drug interactions depends on factors related to: Drug Dose Administration route Pharmacokinetic Pharmacodynamic Herbs Species Dose Administration route Patient Genetic Polymorphism Age Pathological conditions

Many herbs (e.g. St John’s wort, kava and garlic,. coumarins and caffeine) have been identified as substrates, inhibitors and/or inducers of CYP enzymes. Cytochrome P450 Green tea Ginkgo Garlic Genseng ST John’s wort (2 w) CYP

P-glycoprotein Like CYP, P-glycoprotein could cause inhibition, activation, or induction by herbs. Curcumin, ginsenosides, piperine, sylimarin and catechins may affect P-glycoprotein-mediated drug transport. St John’s wort induces the intestinal expression of P-glycoprotein both in isolated cells and in healthy volunteers.

Pharmacodynamic A few pharmacodynamic interactions have also been described. Pharmacodynamicinteractions may be synergetic(e.g. interaction between the anticoagulant warfarinwith antiplatelet herbs), or antagonistic (e.g. kava possesses dopaminergic antagonistic propertiesand hence might reduce the pharmacological activity ofthe anti-parkinson drug levodopa).

The World Health Organization (WHO) defines herbal supplements as "Finished, labelled, medicinal products that contain active ingredients from aerial or underground parts of plants, or other plant material, or combinations of, whether crude state or as other preparations “. WHO Programm on Traditional Medicines: Guidelines for the assessment of herbal medicines. Geneva: World Health Orginization, WHO Programm on Traditional Medicines: Guidelines for the assessment of herbal medicines. Geneva: World Health Orginization, 1991.

32 drugs interacting with herbal medicines in humans. E.g. anticoagulants (warfarin, aspirin and phenprocoumon) sedatives and antidepressants (midazolam, alprazolam&amitriptyline) oral contraceptives anti-HIV agents (indinavir, ritonavir and saquinavir) cardiovascular drug (digoxin) immunosuppressants (cyclosporine and tacrolimus) anticancer drugs (imatinib and irinotecan).

Evidence for herb-drug interactions ► Case reports  Unreported? 70% “don’t ask-don’t tell” ► Lab studies  Define mechanisms ► Recent interest in CYP450 induction ► Human studies  Trials using probe drugs  May be done on healthy population  Genetic polymorphisms De Smet, Br J Clin Pharm 2006; 63:258-67

Drugs that have been reported to interact w herbs Current Pharmaceutical Design, 2006,Vol. 12, No. 35

Drugs that have been reported to interact w herbs Current Pharmaceutical Design, 2006,Vol. 12, No. 35

Drugs that have been reported to interact w herbs Current Pharmaceutical Design, 2006,Vol. 12, No. 35

Drugs that have been reported to interact w herbs Current Pharmaceutical Design, 2006,Vol. 12, No. 35

The majority of reports concern drugs with a narrowtherapeutic index such as warfarin and digoxin. Increasedanticoagulant effects could be expected when warfarinis combined with coumarin- containing herbs (e.g.boldo, fenugreek, papaya, mango) or with antiplatelet herbs(e.g. danshen, garlic, ginkgo). Vitamin K containing herbs (e.g. green tea) can antagonized the anticoagulant effect of warfarin.

Six weeks after starting cranberry juice a 70-year-old man under warfarin was admitted to hospital with an INR >50. He died of a gastrointestinal and pericardial haemorrhage. (Cranberry juice contains antioxidants, including flavonoids, which are know to inhibit CYP enzymes) Grant P. Warfarin and cranberry juice: an interaction.J. Heart. Valve Dis. (2004) 13 25–26.

Interactions with cardiac inotropic drugs In a single-blind, placebo-controlled study. Digoxin St John’s wort Induced PGP Reduce Digoxin Digoxin Gum Guag Reduce digoxin clinical trials

Interactions with antihypertensive drugs Surprisingly, an elderly patient was found to have anincrease in blood pressure after taking ginkgo (a peripheral vasodilator) while receiving a thiazide diuretic. There is no rationalpharmacological mechanism to explain this unusualinteraction.

Interaction with oral hypoglycemic drugs Clinical studies have shown that gumguar reduced the absorption of metformin andglibenclamide. By contrast, anothertrial showed that gum guar enhanced the insulinogenicand blood glucose lowering effect of glibenclamide. A fall in glucose levels has been reported in a 40- year-old diabetic woman taking chlorpropamide and garlic. This event is likelybecause of an additive effect on glucose level. Capasso F., Gaginella T.S., Grandolini G., Izzo A.A. Phytotherapy. A quick reference to herbal medicine, SpringerVerlag, Berlin, Heidelberg, 2003.

INTERACTIONS WITH ANTI- INFLAMMATORY DRUGS Many paper showed that Liquorices increased the plasma prednisolone concentrations in six healthy men. Glycyrrhizin, which is astrong inhibitor of 11 beta- hydroxysteroiddehydrogenase,influences prednisolone pharmacokinetics by inhibiting its metabolism. Chen M.F., Shimada F., Kato H., Yano S., Kanaoka M. Effect of oral administration of glycyrrhizin on the pharmacokinetics of prednisolone. Endocrinol. Jpn. (1991) –174.

STRATEGY FOR ELIMINATING TOXICITY ARISING FROM DRUG-HERB INTERACTIONS 1. PredictingDrug-Herb Interactions It is necessary to assess the clinical risks by predicting qualitatively and quantitatively drug-herb interactions.

STRATEGY FOR ELIMINATING TOXICITY ARISING FROM DRUG-HERB INTERACTIONS 2. Identification of Drugs that Interact with Herb The identification of drugs causing drug-herb interactions and the mechanisms involved are important in term of rational use of therapeutic drugs. The application of high throughput approaches to the study of drug-herb, herb- CYP and herb- PgP interactions is becoming possible. If potential toxic drug- herb interactions have been observed, the combined use of related drugs and herbs should be generally avoided. In some cases where the avoidance is difficult, proper dose adjustment or alternative drugs may be needed.

STRATEGY FOR ELIMINATING TOXICITY ARISING FROM DRUG-HERB INTERACTIONS 3. Therapeutic Drug Monitorin Due to frequent pharmacokinetic drug-herb interactions, monitoring of plasma concentrations of drugs with narrow therapeutic indices are always important in patients also taking herbs.

STRATEGY FOR ELIMINATING TOXICITY ARISING FROM DRUG-HERB INTERACTIONS 4. Design of Hard Drugs to Eliminate Toxicity Arising from Drug-Herb Combinations It appears that the chemical properties of a drug critical for herbal interaction include (i) being a CYP substrate, (ii) being a PgP substrate, (iii) Induction/ inhibition of CYP

Hard drugs :not metabolized by CYPs and/or not transported by PgP. Example: bisphosphonates (e.g. etidronate and alendronate,) and certain ACE inhibitors (e.g. enalaprilat and lisinopril).

Conclusion Although some drug– herb interactions may be clinically insignificant (e.g. interaction between gum guar andpenicillin V), others may have serious consequences (e.g.interaction between St John’s wort and cyclosporine). Withdrawal of a chronically administered herbal product that acts as an inducer in a patient stabilized on effective drug therapy can result in untoward pharmacological or toxic effects

limitation Reported drug-herb interactions are ANECDOTAL (single reports). Herbal medicines are mixtures of more than one active ingredient. makes it difficult to draw useful comparisons between clinical studies or case reports. The likelihood of herb±drug interactions could be higher than drug±druginteractions. fewer than 40% of patients disclose their herbal supplement usage to their physician and many physicians are unaware of the potential for– drug herb interactions.

Take Home Message

Checking for herb-drug interactions ► Natural Standard ( Subscriptions for PDA/desktop available.  Partial database at MedlinePlus.gov ► Natural Medicines Comprehensive Database ( Subscription service.

Induction Induction is a term used to describe a physiologica adaptive response to continued xenobiotic exposure. It is characterized by enhanced gene transcription and/ortranslation, stabilized messenger ribonucleic acid, or inhibited protein turnover. The end result can be increased amounts of proteins that determine drug disposition such as metabolic enzymes or transporters. The dose of the inducer determines its cellular concentration and hence the extent of induction. The resulting clinical effects usually start within a few days of repeated administration. After withdrawal of the inducer, reversal is generally complete within 1 week. Case reports of reduced exposure and reduced degree and/or duration of drug response have often served as mportant stimuli for formal study of herbal–drug interactions [10]. A common in vivo method uses a drug probe that is a relatively safe substance inactivated or eliminated primarily by a single metabolic process (e.g. midazolam and cytochrome P450(CYP)3A4) or transport process (e.g. fexofenadine and P-glycoprotein). increasingly popular is the use of probe ‘cocktails’ that determine the activities of multiple eliminating pathways on a single occasion. The probes are administered before and then after a suitable treatment period with a particular herbal product to examine their effects on clearance of the probe. The molecular mechanisms that govern the inductive response are well established and in vitro tools are available to predict whether herbal products or their chemical constituents might cause a clinically important drug interaction. The most prominent mechanisms for induction are ligand-dependent transcriptional activation of nuclear receptors, such as the pregnane X (PXR), constitutive androstane (CAR) or aryl hydrocarbon receptors (AhR). Convenient cell-based screening assays for activation of nuclear receptors are routinely used. Further investigations in the cultured primary human hepatocyte model are performed to confirm induction of gene expression.